![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 653t CAMBRIDGE ANTIBODY TECHNOLOGY 1 June 1999 For Further Information Contact: Cambridge Antibody Technology David Chiswell, Chief Executive Officer Tel: +44 (0) 1763 263233 John Aston, Finance Director HCC.De Facto City/Financial, Sue Charles Tel: +44 (0) 171 496 3300 Trade/Science, Nikul Odedra CAMBRIDGE ANTIBODY TECHNOLOGY ISSUE OF FURTHER SHARES FOR ACQUISITION OF APTEIN INC Melbourn, UK In July 1998, as previously announced, Cambridge Antibody Technology ("CAT") acquired Aptein Inc., a US company. Aptein's major asset is granted US and European patents in the field of polysome display. The total purchase consideration was up to $11 million. $6 million of the consideration was satisfied by the issue of CAT shares in July 1998, with the balance of up to $5 million in CAT shares to be satisfied after Aptein had received grants of European patents for its key technology and these patents had been sustained through opposition or appeal. A European patent was granted to Aptein in July 1998, and the related period of opposition ended in April 1999. The European Patent Office has now issued formal confirmation that there has been no opposition made to the grant of this patent. Accordingly CAT is issuing a further 1,075,245 CAT ordinary shares to Aptein shareholders in settlement of the balance of the consideration. Application has been made to the London Stock Exchange for these shares to be admitted to the Official List. Notes to Editors Cambridge Antibody Technology: CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 150 people. In March 1997, CAT completed its initial public offering and listing on the London Stock Exchange, raising approximately #41 million. CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. The first two antibody products it developed started clinical trials in 1997, in inflammation and fibrosis. CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute/BASF Pharma and Wyeth-Ayerst. Aptein: Aptein's technology can be viewed as analogous to CAT's phage display technology. The key difference is that rather than displaying large libraries of antibodies on a simple virus (the phage) the libraries of antibodies are displayed on a component of the cell known as a ribosome. The complex of ribosome, mRNA and newly made protein is referred to as a polysome. The polysome is responsible for protein synthesis in the cell. As with phage display, selection techniques allow the isolation, from these libraries, of single molecules, which bind drug targets of interest, or, by using antibodies, the isolation of the targets themselves. END MSCBIGBUGGDCCCI
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions